Clinical Report: Exploring the Role of Long Non-Coding RNAs in Forecasting Immunotherapy Outcomes

Overview

This systematic review evaluates the prognostic value of long non-coding RNAs (lncRNAs) in predicting outcomes for cancer patients treated with immune checkpoint inhibitors (ICIs).

Background

The advent of immune checkpoint inhibitors has significantly altered cancer treatment paradigms; however, their efficacy is limited to a subset of patients. Reliable biomarkers are essential for predicting patient responses to ICIs.

Data Highlights

The review included 31 studies that assessed lncRNA expression in adult cancer patients treated with ICIs.

Key Findings

• LncRNA-based signatures can stratify patients into groups with significantly different survival outcomes.
• lncRNAs are associated with variations in ICI response across multiple cancer types.
• Dysregulation of specific lncRNAs, such as NEAT1 and HCP5, correlates with immune checkpoint regulation.

Clinical Implications

Further research is needed to validate these findings in prospective studies.

Conclusion

LncRNAs are being investigated as prognostic and predictive biomarkers for patients undergoing ICI treatment.

Related Resources & Content

1. Frontiers in Immunology, 2026 -- Comprehensive exploration of the role of multimodal programmed cell death- associated lncRNAs in the prognosis and immunity of glioma
2. asco ai in oncology, 2026 -- Improved Immunotherapy Response Prediction in NSCLC With Deep-Learning Radiomic Biomarker
3. asco ai in oncology, 2026 -- Transcriptomic Classifier for Predicting Neoadjuvant Immunotherapy Response in Triple-Negative Breast Cancer
4. Frontiers in Oncology, 2026 -- Integrating chemokine signatures and multi-omic biomarkers to predict immunotherapy response in non-small cell lung cancer: a comprehensive narrative review
5. Journal of Clinical Oncology, 2026 -- Mismatch Repair and Microsatellite Instability Testing for Immune Checkpoint Inhibitor Therapy: ASCO Endorsement of College of American Pathologists Guideline
6. Long non-coding RNAs and Their Potential Role in Predicting Immunotherapy Response and Prognosis: A Systematic Review
7. Addendum 1: Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma
8. Mismatch Repair and Microsatellite Instability Testing for Immune Checkpoint Inhibitor Therapy: ASCO Endorsement of College of American Pathologists Guideline | Journal of Clinical Oncology